MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-026-03075-1

Медицинская библиотека · Leukemia · 2026

Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.

Mariotti Estefania Gauto, Kumar Shaji, Gonsalves Wilson, Kapoor Prashant, Buadi Francis, Hayman Suzanne, Abdallah Nadine, Binder Moritz, Cook Joselle, Dispenzieri Angela, Dingli David, Gertz Morie A, Kourelis Taxiarchis, Leung Nelson, Lin Yi, Siddiqui Mustaqeem, Go Ronald, Muchtar Eli, Warsame Rahma, Jevremovic Dragan, Kyle Robert A, Rajkumar S Vincent, Zanwar Saurabh

СтатьяПеревод в очереди

Аннотация

Measurable residual disease (MRD) assessment has become central to risk-adapted treatment strategies in multiple myeloma, yet the prognostic value of MRD negativity following autologous stem cell transplantation (ASCT) across individual high-risk cytogenetic abnormalities (HRCAs) remains unclear. We analyzed 351 newly diagnosed patients who achieved MRD negativity (sensitivity 2.4 × 10-6) between day 60-100 following ASCT and had baseline cytogenetic data available. Median follow-up was 50.4 months. Standard-risk cytogenetics were present in 46% (n = 162), while 34% (n = 118) had one HRCA and 20% (n = 71) had ≥2 HRCAs. Despite uniform MRD negativity, several HRCAs continued to confer inferior progression-free survival (PFS). Compared with the standard-risk group (4-year PFS 84%), patients with del(17p), 1q21+, t(4;14), or MAF translocations [t(14;16)/t(14;20)] had significantly lower 4-year PFS rates: 56% (HR 2.89; p = 0.0001), 60% (HR 2.46; p = 0.0001), 43% (HR 3.50; p = 0.0001), and 58% (HR 2.51; p = 0.01), respectively. Isolated del(17p) and 1q21+ also conferred inferior PFS. The 4-year PFS was 65% for patients with one HRCA (HR 2.31; p = 0.0004) and 55% for those with ≥2 HRCAs (HR 2.75; p = 0.0001). In this large MRD-negative post-ASCT cohort, several HRCAs, including isolated HRCAs, were associated with inferior PFS, suggesting a potential persistence of high-risk biology despite early MRD negativity.

Для цитирования: Mariotti Estefania Gauto, Kumar Shaji, Gonsalves Wilson, Kapoor Prashant, Buadi Francis, Hayman Suzanne, Abdallah Nadine, Binder Moritz, Cook Joselle, Dispenzieri Angela, Dingli David, Gertz Morie A, Kourelis Taxiarchis, Leung Nelson, Lin Yi, Siddiqui Mustaqeem, Go Ronald, Muchtar Eli, Warsame Rahma, Jevremovic Dragan, Kyle Robert A, Rajkumar S Vincent, Zanwar Saurabh. Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.. Leukemia. 2026. DOI: 10.1038/s41375-026-03075-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.